View company's website

1 known investors

Eledon develops tegoprubart, an anti-CD40L antibody immunosuppressant for organ transplant recipients, aimed at preventing transplant rejection and extending organ longevity. The company is conducting clinical trials in kidney transplantation with expansion into liver transplants and xenotransplantation.

BiotechLongevityMedical Devices